At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 229 enrolled
Drug / intervention
Relatlimab +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
In Brief
A Phase 2 clinical trial evaluating Relatlimab, Nivolumab, and 2 other interventions for Advanced Cancer. Completed, enrolled 229 participants across 22 sites in 7 countries.
Detailed Summary
The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in immunotherapy-naive and pretreated populations across select advanced tumor types.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancer
CountriesAustralia, France, Italy, Spain, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartMay 2018
Primary CompletionFeb 2025
TodayJul 2026
First PostedMar 8, 2018
Enrollment StartMay 30, 2018
Primary CompletionFeb 19, 2025
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 8.3 years ago
Interventions
Relatlimabbiological
Specified dose on specified days
Nivolumabbiological
Specified dose on specified days
BMS-986205drug
Specified dose on specified days
Ipilimumabbiological
Specified dose on specified days